Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Larson Financial Group LLC

Larson Financial Group LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,493 shares of the biopharmaceutical company’s stock after purchasing an additional 276 shares during the period. Larson Financial Group LLC’s holdings in Gilead Sciences were worth $109,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tompkins Financial Corp increased its position in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $29,000. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $29,000. Palisade Asset Management LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at $29,000. Finally, Sachetta LLC purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.5 %

Shares of NASDAQ GILD traded up $0.99 during mid-day trading on Wednesday, reaching $68.75. The company had a trading volume of 4,100,409 shares, compared to its average volume of 7,500,952. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The stock has a market capitalization of $85.65 billion, a PE ratio of 190.83, a price-to-earnings-growth ratio of 2.87 and a beta of 0.18. The stock’s 50 day moving average is $66.17 and its 200-day moving average is $71.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.37 earnings per share. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.48%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GILD shares. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a report on Wednesday, April 24th. UBS Group decreased their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley decreased their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, TD Cowen decreased their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $84.00.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.